Industry veteran Christine Obercian will serve as Executive Director
for the clinical trial site super network.
COLUMBUS, GA, September 08, 2023 /24-7PressRelease/ — hyperCORE International, a collaborative network of clinical trial sites across North America, is excited to welcome Christy Obercian, MS, PMP as Executive Director. Bringing a wealth of experience in clinical operations leadership, program management, and organizational development, Obercian is poised to continue expanding hyperCORE’s reach and capabilities across the clinical research arena.
Obercian holds over 25 years of industry experience and has served at the executive level for various global biotech and pharmaceutical companies, CROs, and service providers. With a dynamic background in strategic partnerships, business development, vendor and site management, governance, and resource management, she keenly understands the intricate landscape of clinical trials. She has contributed to hundreds of drug, device, biologic and genetic clinical trials, spanning all phases, populations, and therapeutic areas, including leading teams that brought Advair, Lyrica, Abreva, Chantix, Crestor, Atacand, and Viagra to the market.
Obercian is ready to lead into the next era of growth for hyperCORE, as the company continues to shape the future of clinical research through groundbreaking operational alliances. With her focus on hyperCORE’s mission to accelerate streamlined clinical research, she expressed she is “excited to be a part of the hyperCORE super-network of experienced clinical research sites and looking forward to collaboratively advancing the rigorous execution of sponsors’ research and commitment to quality, subject safety, data integrity, and diversity.”
Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 100 active research sites on two continents and five countries. Each of its alliance partners have decades of clinical research experience and have collectively completed more than 7,000 studies helping to evaluate thousands of new drugs and treatments in more than 140,000 randomized patients. Each partner operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.
hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.
For the original version of this press release, please visit 24-7PressRelease.com here